KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesOther Gross PP&E AdjustmentsShares IssuedShares Outstanding
Ratios

Rigel Pharmaceuticals (RIGL) Accumulated Depreciation & Amortization (2016 - 2024)

Historic Accumulated Depreciation & Amortization for Rigel Pharmaceuticals (RIGL) over the last 15 years, with Q4 2024 value amounting to $100000.0.

  • Rigel Pharmaceuticals' Accumulated Depreciation & Amortization fell 5000.0% to $100000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $100000.0, marking a year-over-year decrease of 5000.0%. This contributed to the annual value of $100000.0 for FY2024, which is 5000.0% down from last year.
  • As of Q4 2024, Rigel Pharmaceuticals' Accumulated Depreciation & Amortization stood at $100000.0, which was down 5000.0% from $200000.0 recorded in Q4 2023.
  • Rigel Pharmaceuticals' 5-year Accumulated Depreciation & Amortization high stood at $1.2 million for Q4 2021, and its period low was $100000.0 during Q4 2024.
  • Over the past 5 years, Rigel Pharmaceuticals' median Accumulated Depreciation & Amortization value was $700000.0 (recorded in 2020), while the average stood at $620000.0.
  • Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first tumbled by 9463.4% in 2020, then skyrocketed by 7142.86% in 2021.
  • Rigel Pharmaceuticals' Accumulated Depreciation & Amortization (Quarter) stood at $700000.0 in 2020, then skyrocketed by 71.43% to $1.2 million in 2021, then dropped by 25.0% to $900000.0 in 2022, then tumbled by 77.78% to $200000.0 in 2023, then tumbled by 50.0% to $100000.0 in 2024.
  • Its Accumulated Depreciation & Amortization stands at $100000.0 for Q4 2024, versus $200000.0 for Q4 2023 and $900000.0 for Q4 2022.